

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C12N 15/49, 15/70, 15/79 C12P 21/08, A61K 39/21, 39/42 G01N 33/53, 33/564, 33/569	<b>A1</b>	<b>(11) International Publication Number:</b> WO 92/15684 <b>(43) International Publication Date:</b> 17 September 1992 (17.09.92)
<b>(21) International Application Number:</b> PCT/US92/01421 <b>(22) International Filing Date:</b> 27 February 1992 (27.02.92)  <b>(30) Priority data:</b> 661,370 28 February 1991 (28.02.91) US  <b>(71) Applicant:</b> CAMBRIDGE BIOTECH CORPORATION [US/US]; 365 Plantation Street, Worcester, MA 01605 (US).  <b>(72) Inventors:</b> YOUNG, Eli ; 10 Prince Way, Sharon, MA 02067 (US). DAVIS, Deborah ; 140 Redstone Hill Road, Apt. 2, Sterling, MA 01564 (US). STOREY, James, R. ; 15 Lake Street, Linwood, MA 01525 (US). BELTZ, Gerald ; 42 Downing Road, Lexington, MA 02173 (US).	<b>(74) Agents:</b> FOX, Samuel, L. et al.; Sterne, Kessler, Goldstein & Fox, 1225 Connecticut Avenue, N.W., Suite 300, Washington, DC 20036 (US).  <b>(81) Designated States:</b> AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> RECOMBINANT FIV GLYCOPROTEIN 160 AND p24 GAG PROTEIN  <b>(57) Abstract</b>  Feline immunodeficiency virus antigens from gp160 envelope protein, gp120 envelope protein and p24 gag protein, useful for the diagnosis, treatment, and prevention of FIV. The invention may also be used to purify FIV.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

-1-

## TITLE OF THE INVENTION

RECOMBINANT FIV GLYCOPROTEIN 160 AND p24 GAG PROTEIN

FIELD OF THE INVENTION

5 The present invention relates generally to the fields of hematology, immunology and recombinant genetics. The invention specifically relates to recombinant feline immunodeficiency virus glycoprotein 160 envelope protein and fragments thereof, and p24 gag protein and fragments thereof. In another aspect,  
10 it relates to the use of the FIV antigens and fragments to induce, in a feline, antibodies to FIV.

DESCRIPTION OF THE BACKGROUND ART

15 Feline immunodeficiency virus (FIV), formerly called feline T lymphotropic lentivirus (Pederson et al., Science, 235:790 (1987)), has been identified in the United States, the United Kingdom (Harbour et al., Vet Rec, 122:84 (1988)), Japan (Ishida et al., Jpn J Vet Sci, 50:39 (1988)), Australia (Sabine et al., Aust Vet Practit, 18:105 (1988)), and New Zealand (Swinney  
20 et al., NZ Vet J, 37:41 (1989)). The virus appears to be spread by horizontal transmission, predominantly by bite wounds (Yamamoto et al., Am. J. Vet. Res., 8:1246 (1988); Friend et al., Aust. Vet J., 67:237 (1990). FIV has been classified as a member of the  
25 subfamily Lentivirinae in the family Retroviridae. This is the family that includes human and simian immunodeficiency viruses, equine infectious anaemia,

-2-

maedi visna of sheep and caprine-arthritis encephalitis viruses (CAEV).

Cloning and sequencing of FIV has confirmed it to be a lentivirus by its genomic organization and antigenic similarity of its core proteins to those of visna virus and CAEV (Olmsted et al., Proc. Natl. Acad. Sci. USA, 86:2448 (1989); Talbott et al., Proc. Natl. Acad. Sci. USA, 86:5743 (1989); Dow et al., Journal Of Acquired Immune Deficiency Syndromes, 3:658 (1990).

Until the present time, however, very little information has been available regarding the outer shell, or envelope, of the feline immunodeficiency virus. Inasmuch as an elucidation of envelope proteins would be of great value in understanding and modulating the immunological characteristics of FIV, a need has continued to exist for such data.

#### SUMMARY OF THE INVENTION

Accordingly, the present inventors have succeeded in cloning and expressing novel envelope proteins and protein fragments of FIV, which are useful in the diagnosis and treatment of this immune condition. Specifically, the inventors report the FIV glycoprotein 160 envelope protein, as well as the FIV 0.4 envelope protein, which is an amplified product of the FIV gp160 envelope protein. The inventors also report the novel FIV 1.2 envelope protein that is an amplified product obtained from the region of FIV envelope from position 6996 to 8129.

In addition to the novel envelope proteins and fragments, the inventors have successfully identified p24 gag protein from FIV which is also useful in the

-3-

diagnosis and treatment of FIV. The inventors have further identified FIV 0.6 which is an amplified product obtained from FIV gag protein.

5 It is an object of the present invention, then, to provide for a method of diagnosing the infection of a feline by FIV. The present invention thus provides an important advance in the study and therapy of feline immune deficiency syndromes.

10 The work presented here demonstrates that recombinant FIV 0.4 envelope protein may be expressed by a transformed cell. The production of recombinant FIV 0.4 envelope protein makes possible new assays and treatments for FIV. It is therefore an object of the present invention to use recombinant proteins from the  
15 gp160 envelope protein and the gag protein to develop vaccines in the prevention of FIV infection in cats.

Thus in one embodiment, there is provided according to the invention recombinant functionally active feline immunodeficiency virus 0.4 envelope protein, or  
20 a functional or chemical derivative thereof.

In yet another embodiment is provided the FIV gp160 derived 0.4 envelope fragment which is produced by eukaryotic cells. Yet another embodiment of the invention comprises the plasmid pLCBCOFIV0.4. There  
25 is also provided according to this invention, methods for producing FIV gp160 derived 0.4 envelope protein, comprising culturing the transformed cell under conditions allowing expression of the gp160 derived 0.4 envelope fragment, and recovering said gp160  
30 derived 0.4 envelope protein.

In yet another embodiment, the present invention provides for an antibody against the FIV envelope protein of the invention.

-4-

Further a method of purifying FIV from a sample is provided according to the present invention, comprising contacting said sample with the antibody of the invention, so as to form a complex between said antibody and FIV in said sample, and removing the FIV from said antibody so as to obtain purified FIV.

Moreover, a method of detecting FIV in a sample comprising contacting said sample with the antibody of the invention, wherein said antibody is detectably labeled, so as to form a complex between FIV in said sample and said detectably labeled antibody, and detecting the complexed or uncomplexed detectably labeled antibody.

An additional embodiment of the current invention comprises a pharmaceutical preparation comprising the antibody of the invention. In another embodiment, there is provided a process for the preparation of a pharmaceutical composition useful for inducing the production in a cat of antibodies to FIV, the process comprising admixing an immunologically effective amount of the polypeptide comprising the amino acid sequence of the gp160, gp120 or FIV 0.4 envelope protein together with a pharmaceutically acceptable carrier.

These and other non-limiting embodiments of the present invention will be apparent to those of skill from the following detailed description of the invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the sequences of the PCR primers. The underlined regions indicate BamHI restriction sites.

-5-

Figure 2 shows the position of the 0.4 amplified product relative to the entire gp 160 envelope protein.

Figure 3 shows purified recombinant proteins from FIV. Lane 1 contains the molecular weight markers. Lane 2 is a recombinant protein from the gp 120 region of the FIV envelope gene. Lane 3 is a recombinant FIV p24 gag protein. Lane 4 contains the FIV 0.4 envelope diagnostic protein.

Figure 4 shows the reactivity of sera from infected cats with the induced FIV 0.4 protein. Lanes 1-10 demonstrate that the protein reacted specifically with sera from FIV-infected cats. Lanes 11-15 are negative controls.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

In the following description, reference will be made to various methodologies known to those of skill in the art of molecular biology and immunology. Publications and other materials setting forth such known methodologies to which reference is made are incorporated herein by reference in their entireties as though set forth in full.

Standard reference works setting forth the general principles of recombinant DNA technology include Watson, J.D. et al., Molecular Biology of the Gene, Volumes I and II, The Benjamin/Cummings Publishing Company, Inc., publisher, Menlo Park, CA (1987); Darnell, J.E. et al., Molecular Cell Biology, Scientific American Books, Inc., publisher, New York, N.Y. (1986); Lewin, B.M., Genes II, John Wiley & Sons, publishers, New York, N.Y. (1985); Old, R.W., et al., Principles of Gene Manipulation: An Introduction to



-6-

Genetic Engineering, 2d edition, University of California Press, publisher, Berkeley, CA (1981); and Maniatis, T., et al., Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor Laboratory, publisher, Cold Spring Harbor, NY (1989).

#### DEFINITIONS

The term "immunologically effective amount" as used in the invention, is meant to denote the amount of FIV 0.4 envelope protein or FIV gp160 or FIV gp120 envelope protein or FIV 0.6 gag fragment which is necessary to induce production in a cat of antibodies which will bind to FIV epitopes.

By "cloning" is meant the use of in vitro recombination techniques to insert a particular gene or other DNA sequence into a vector molecule. In order to successfully clone a desired gene, it is necessary to employ methods for generating DNA fragments, for joining the fragments to vector molecules, for introducing the composite DNA molecule into a host cell in which it can replicate, and for selecting the clone having the target gene from amongst the recipient host cells.

By "vector" is meant a DNA molecule, derived from a plasmid or bacteriophage, into which fragments of DNA may be inserted or cloned. A vector will contain one or more unique restriction sites, and may be capable of autonomous replication in a defined host or vehicle organism such that the cloned sequence is reproducible. Thus, by "DNA expression vector" is meant any autonomous element capable of replicating in a host independently of the host's chromosome, after additional sequences of DNA have been incorporated

-7-

into the autonomous element's genome. Such DNA expression vectors include bacterial plasmids and phages.

5 By "substantially pure" is meant any antigen of the present invention, or any gene encoding any such antigen, which is essentially free of other antigens or genes, respectively, or of other contaminants with which it might normally be found in nature, and as  
10 such exists in a form not found in nature. By "functional derivative" is meant the "fragments," "variants," "analogues," or "chemical derivatives" of a molecule. A "fragment" of a molecule, such as any of the DNA sequences of the present invention, is meant to refer to any nucleotide subset of the molecule. A  
15 "variant" of such molecule is meant to refer to a naturally occurring molecule substantially similar to either the entire molecule, or a fragment thereof. An "analog" of a molecule is meant to refer to a non-natural molecule substantially similar to either the  
20 entire molecule or a fragment thereof.

A molecule is said to be "substantially similar" to another molecule if the sequence of amino acids in both molecules is substantially the same. Substantially similar amino acid molecules will possess a  
25 similar biological activity. Thus, provided that two molecules possess a similar activity, they are considered variants as that term is used herein even if one of the molecules contains additional amino acid residues not found in the other, or if the sequence of  
30 amino acid residues is not identical. As used herein, a molecule is said to be a "chemical derivative" of another molecule when it contains additional chemical moieties not normally a part of the molecule. Such moieties may improve the molecule's solubility,

-8-

absorption, biological half life, etc. The moieties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing Co., Easton, Penn. (1980).

Similarly, a "functional derivative" of a gene of the FIV 0.4 envelope protein, FIV 1.2 envelope protein or FIV 0.6 fragment of the present invention is meant to include "fragments," "variants," or "analogues" of the gene, which may be "substantially similar" in nucleotide sequence, and which encode a molecule possessing similar activity to the FIV 0.4 peptide.

Thus, as used herein, FIV 0.4 envelope protein, FIV 1.2 envelope protein and FIV 0.6 are also meant to include any functional derivative, fragments, variants, analogues, chemical derivatives which may be substantially similar to the peptides FIV 0.4, FIV 1.2 and FIV 0.6 and which possess similar activity.

A DNA sequence encoding the FIV 0.4 envelope protein, FIV 1.2 envelope protein or FIV 0.6 fragment of the present invention, or its functional derivatives, may be recombined with vector DNA in accordance with conventional techniques, including blunt-ended or staggered-ended termini for ligation, restriction enzyme digestion to provide appropriate termini, filling in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and ligation with appropriate ligases. Techniques for such manipulations are disclosed by Maniatis, T., et al., supra, and are well known in the art.

A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a polypeptide if it contains nucleotide sequences which contain transcriptional and translational regulatory information and such sequences are "operably linked" to nucleotide sequences which encode the polypeptide. An operable linkage is a linkage in which the regulatory DNA sequences and the DNA sequence sought to be expressed are connected in such a way as to permit gene expression. The precise nature of the regulatory regions needed for gene expression may vary from organism to organism, but shall in general include a promoter region which, in prokaryotes, contains both the promoter (which directs the initiation of RNA transcription) as well as the DNA sequences which, when transcribed into RNA, will signal the initiation of protein synthesis. Such regions will normally include those 5'-non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.

If desired, the non-coding region 3' to the gene sequence coding for the protein may be obtained by the above-described methods. This region may be retained for its transcriptional termination regulatory sequences, such as termination and polyadenylation. Thus, by retaining the 3'-region naturally contiguous to the DNA sequence coding for the protein, the transcriptional termination signals may be provided. Where the transcriptional termination signals are not satisfactorily functional in the expression host cell, then a 3' region functional in the host cell may be substituted.

Two DNA sequences (such as a promoter region sequence and a FIV 0.4 envelope protein encoding

-10-

sequence) are said to be operably linked if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region sequence to direct the transcription of the FIV 0.4 envelope protein gene sequence, or (3) interfere with the ability of the FIV 0.4 envelope gene sequence to be transcribed by the promoter region sequence. A promoter region would be operably linked to a DNA sequence if the promoter were capable of effecting transcription of that DNA sequence. Thus, to express the protein, transcriptional and translational signals recognized by an appropriate host are necessary.

The present invention encompasses the expression of the FIV 0.4 envelope protein, FIV 1.2 envelope protein, and FIV 0.6 gag fragment (or a functional derivative thereof) in either prokaryotic or eukaryotic cells, although prokaryotic expression is preferred.

Antibodies according to the present invention may be prepared by any of a variety of methods. For example, cells expressing the FIV 0.4 envelope protein, or a functional derivative thereof, can be administered to an animal in order to induce the production of sera containing polyclonal antibodies that are capable of binding the chimera.

In a preferred method, antibodies according to the present invention are monoclonal antibodies. Such monoclonal antibodies can be prepared using hybridoma technology (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., In: Monoclonal Antibodies and T-Cell Hybridomas,

-11-

Elsevier, N.Y., pp. 563-681 (1981)). In general, such procedures involve immunizing an animal with the FIV 0.4 envelope protein antigen. The splenocytes of such animals are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands, J.R., et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the FIV 0.4 envelope protein antigen.

Antibodies according to the present invention also may be polyclonal, or, preferably, region specific polyclonal antibodies.

Antibodies against the FIV 0.4 envelope protein, the FIV 1.2 envelope protein and the FIV gag 0.6 protein according to the present invention are well suited for use in standard immunodiagnostic assays known in the art, including such immunometric or "sandwich" assays as the forward sandwich, reverse sandwich, and simultaneous sandwich assays. The antibodies may be used in any number of combinations as may be determined by those of skill without undue experimentation to effect immunoassays of acceptable specificity, sensitivity, and accuracy for the receptor antigen or equivalents thereof.

Standard reference works setting forth general principles of immunology include Roitt, I., Essential Immunology, Sixth Ed., Blackwell Scientific Publications, Publisher, Oxford (1988); Kimball, J. W., Introduction to Immunology, Second Ed., Macmillan

-12-

Publishing Co., Publisher, New York (1986); Roitt, I.,  
et al., Immunology, Gower Medical Publishing Ltd.,  
Publisher, London, (1985); Campbell, A., "Monoclonal  
Antibody Technology," in, Burdon, R., et al., eds.,  
5 Laboratory Techniques in Biochemistry and Molecular  
Biology, Volume 13, Elsevier, Publisher, Amsterdam  
(1984); Klein, J., Immunology: The Science of Self-  
Nonsel Self Discrimination, John Wiley & Sons, Publisher,  
New York (1982); and Kennett, R., et al., eds.,  
10 Monoclonal Antibodies, Hybridoma: A New Dimension in  
Biological Analyses, Plenum Press, Publisher, New York  
(1980).

By "detecting" it is intended to include deter-  
mining the presence or absence of a substance or  
15 quantifying the amount of a substance. The term thus  
refers to the use of the materials, compositions, and  
methods of the present invention for qualitative and  
quantitative determinations.

The isolation of other hybridomas secreting  
20 monoclonal antibodies of the same specificity as those  
described herein can be accomplished by the technique  
of anti-idiotypic screening. Potocmjak, et al.,  
Science 215:1637 (1982). Briefly, an anti-idiotypic  
antibody is an antibody which recognizes unique  
25 determinants present on the antibody produced by the  
clone of interest. The anti-idiotypic antibody is  
prepared by immunizing an animal of the same strain  
used as the source of the monoclonal antibody with the  
monoclonal antibody of interest. The immunized animal  
30 will recognize and respond to the idiotypic determi-  
nants of the immunizing antibody by producing antibody  
to these idiotypic determinants (anti-idiotypic  
antibody).

-13-

For replication, the hybrid cells may be cultivated both in vitro and in vivo. High in vivo production makes this the presently preferred method of culture. Briefly, cells from the individual hybrid strains are injected intraperitoneally into pristine-primed BALB/c mice to produce ascites fluid containing high concentrations of the desired monoclonal antibodies. Monoclonal antibodies of isotype IgM or IgG may be purified from cultured supernatants using column chromatography methods well known to those of skill in the art.

Antibodies according to the present invention are particularly suited for use in immunoassays wherein they may be utilized in liquid phase or bound to a solid phase carrier. In addition, the antibodies in these immunoassays can be detectably labeled in various ways.

There are many different labels and methods of labeling known in the art. Examples of the types of labels which can be used in the present invention include, but are not limited to, enzymes, radioisotopes, fluorescent compounds, chemiluminescent compounds, bioluminescent compounds and metal chelates. Those of ordinary skill in the art will know of other suitable labels for binding to antibodies, or will be able to ascertain the same by the use of routine experimentation. Furthermore, the binding of these labels to antibodies can be accomplished using standard techniques commonly known to those of ordinary skill in the art.

One of the ways in which antibodies according to the present invention can be detectably labeled is by linking the antibody to an enzyme. This enzyme, in turn, when later exposed to its substrate, will react



-14-

with the substrate in such a manner as to produce a chemical moiety which can be detected as, for example, by spectrophotometric or fluorometric means. Examples of enzymes which can be used to detectably label antibodies include malate dehydrogenase, staphylococcal nuclease, delta-V-steroid isomerase, yeast alcohol dehydrogenase,  $\alpha$ -glycerophosphate dehydrogenase, triose phosphate isomerase, biotin-avidin peroxidase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-VI-phosphate dehydrogenase, glucoamylase and acetylcholine esterase.

The presence of detectably labeled antibodies also can be detected by labeling the antibodies with a radioactive isotope which then can be determined by such means as the use of a gamma counter or a scintillation counter. Isotopes which are particularly useful for the purpose of the present invention are  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ ,  $^{51}\text{Cr}$ ,  $^{36}\text{Cl}$ ,  $^{57}\text{Co}$ ,  $^{58}\text{Co}$ ,  $^{59}\text{Fe}$  and  $^{75}\text{Se}$ .

It is also possible to detect the binding of detectably labeled antibodies by labeling the antibodies with a fluorescent compound. When a fluorescently labeled antibody is exposed to light of the proper wave length, its presence then can be detected due to the fluorescence of the dye. Among the most commonly used fluorescent labeling compounds are fluorescein, isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

The antibodies of the invention also can be detectably labeled using fluorescent emitting metals such as  $^{152}\text{Eu}$ , or others of the lanthanide series. These metals can be attached to the antibody molecule using such metal chelating groups as diethylene-

-15-

triaminepentaacetic acid (DTPA) or ethylenediamine-tetraacetic acid (EDTA).

Antibodies also can be detectably labeled by coupling them to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of the chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salts, oxalate ester, and dioxetane.

Likewise, a bioluminescent compound may be used to label the antibodies according to the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent antibody is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling include luciferin, luciferase and aequorin.

The antibodies and substantially purified antigen of the present invention are ideally suited for the preparation of a kit. Such a kit may comprise a carrier means being compartmentalized to receive in close confinement therewith one or more container means such as vials, tubes and the like, each of said container means comprising the separate elements of the assay to be used.

The types of assays which can be incorporated in kit form are many, and include, for example, competitive and non-competitive assays. Typical examples of assays which can utilize the antibodies of the invention are radioimmunoassays (RIA), enzyme immunoassays

-16-

(EIA), enzyme-linked immunosorbent assays (ELISA), and immunometric, or sandwich, immunoassays.

5 By the term "immunometric assay" or "sandwich immunoassay," it is meant to include simultaneous sandwich, forward sandwich and reverse sandwich immunoassays. These terms are well understood by those skilled in the art. Those of skill will also appreciate that antibodies according to the present invention will be useful in other variations and forms of assays which are presently known or which may be developed in the future. These are intended to be included within the scope of the present invention.

10 In the preferred mode for performing the assays it is important that certain "blockers" be present in the incubation medium (usually added with the labeled soluble antibody). The "blockers" are added to assure that non-specific proteins, protease, or feline antibodies to mouse immunoglobulins present in the experimental sample do not cross-link or destroy the antibodies on the solid phase support, or the radiolabeled indicator antibody, to yield false positive or false negative results. The selection of "blockers" therefore adds substantially to the specificity of the assays described in the present invention.

25 It has been found that a number of nonrelevant (i.e. nonspecific) antibodies of the same class or subclass (isotype) as those used in the assays (e.g. IgG<sub>1</sub>, IgG<sub>2a</sub>, IgM, etc.) can be used as "blockers." The concentration of the "blockers" (normally 1-100 microgs/microl) is important, in order to maintain the proper sensitivity yet inhibit any unwanted interference by mutually occurring cross reactive proteins in feline serum. In addition, the buffer system containing the "blockers" needs to be optimized. Preferred

30

-17-

5 buffers are those based on weak organic acids, such as imidazole, HEPPS, MOPS, TES, ADA, ACES, HEPES, PIPES, TRIS, and the like, at physiological pH ranges. Somewhat less preferred buffers are inorganic buffers such as phosphate, borate or carbonate. Finally, known protease inhibitors should be added (normally at 0.01-10 microgs/ml) to the buffer which contains the "blockers."

10 There are many solid phase immunoadsorbents which have been employed and which can be used in the present invention. Well known immunoadsorbents include glass, polystyrene, polypropylene, dextran, nylon and other materials, in the form of tubes, beads, and microtiter plates formed from or coated with such materials, and the like. The immobilized antibodies can be either covalently or physically bound to the solid phase immunoadsorbent, by techniques such as covalent bonding via an amide or ester linkage, or by adsorption. Those skilled in the art will know many other suitable solid phase immuno-adsorbents and methods for immobilizing antibodies thereon, or will be able to ascertain such, using no more than routine experimentation.

25 For in vivo, in vitro or in situ diagnosis, labels such as radionuclides may be bound to antibodies according to the present invention either directly or by using an intermediary functional group. An intermediary group which is often used to bind radio-isotopes which exist as metallic cations to antibodies is diethylenetriaminepentaacetic acid (DTPA). Typical examples of metallic cations which are bound in this manner are:  $^{99m}\text{Tc}$ ,  $^{123}\text{I}$ ,  $^{111}\text{In}$ ,  $^{131}\text{I}$ ,  $^{97}\text{Ru}$ ,  $^{67}\text{Cu}$ ,  $^{67}\text{Ga}$  and  $^{68}\text{Ga}$ . The antibodies of the invention can also be labeled with non-radioactive isotopes for purposes of

30

-18-

diagnosis. Elements which are particularly useful in this manner are  $^{157}\text{Gd}$ ,  $^{55}\text{Mn}$ ,  $^{162}\text{Dy}$ ,  $^{52}\text{Cr}$  and  $^{56}\text{Fe}$ .

5 The antigens of the invention may be isolated in substantially pure form employing antibodies according to the present invention. Thus, an embodiment of the present invention provides for substantially pure FIV 0.4 envelope protein, FIV 1.2 envelope protein, and FIV 0.6 gag protein, said antigens characterized in they are recognized by and bind to antibodies  
10 according to the present invention. In another embodiment, the present invention provides a method of isolating or purifying the FIV 0.4 envelope protein, FIV 1.2 envelope protein and FIV 0.6 gag protein antigens, by forming a complex of said antigen with  
15 one or more antibodies directed against the FIV 0.4 envelope protein, FIV 1.2 envelope protein and FIV 0.6 gag protein respectively.

The substantially pure antigens of the present invention may in turn be used to detect or measure  
20 antibodies to either FIV 0.4 envelope protein, FIV 1.2 envelope protein or FIV 0.6 gag protein in a sample, such as serum or urine. Thus, one embodiment of the present invention comprises a method of detecting the presence or amount of antibody to the FIV 0.4 envelope  
25 protein antigen in a sample, comprising contacting said sample containing said antibody to the FIV 0.4 envelope antigen with detectably labeled FIV 0.4 envelope protein, and detecting said label. It will be appreciated that immunoreactive fractions and  
30 immunoreactive analogues of the fragment also may be used. By the term "immunoreactive fraction" is intended any portion of the FIV 0.4 envelope protein antigen which demonstrates an equivalent immune response to an antibody directed against the receptor

-19-

chimera. By the term "immunoreactive analogue" is intended a protein which differs from the receptor fragment by one or more amino acids, but which demonstrates an equivalent immunoresponse to an antibody of the invention.

The pharmaceutical compositions of the invention may be administered to any animal which may experience the beneficial effects of the compounds of the invention. Foremost among such animals are felines, although the invention is not intended to be so limited.

The manner and method of carrying out the present invention may be more fully understood by those of skill by reference to the following examples, which examples are not intended in any manner to limit the scope of the present invention or of the claims directed thereto.

#### EXAMPLE I

##### Construction of FIV Envelope and GAG Expressing Clones

Genomic DNA was extracted from FIV-infected feline peripheral blood leukocytes. FIV published sequence data (Talbot *et al.*, *Proc. Natl. Acad. Sci.*, 86: 5743 (1989)) was used to create oligonucleotide primers for polymerase chain reaction. The primers amplify the region of FIV envelope from position 8178 to 8576 and also contain BamHI restriction sites with GC-rich clamps at each 5' end to simplify cloning. Figure 1 details the sequence of these primers.

Oligonucleotides used as primers were synthesized by the phosphoroamidite method using an automated DNA synthesizer (Milligen). Prior to amplification, genomic DNA was heat denatured by boiling for five minutes and then was added to the PCR reaction mixes

-20-

at a final concentration of 1 µg per reaction. The PCR reaction mix contained final concentrations of each of the following: 50mM KCl, 10mM Tris HCl, pH 8.3 at room temperature, 0.01% gelatin, 1.5mM MgCl<sub>2</sub>, 320 µM of each dATP, dTTP, dCTP, and dGTP and 0.77 µM of each primer. The PCR reactions were conducted in the Techne Programmable Driblock PHC-1 with the following thermal profile: 95 degrees celsius for 1 minute, 37 degrees celsius for 1 minute, and 72 degrees celsius for 3 minutes for 35 cycles with a final extension at 72 degrees for 5 minutes.

The position of the 0.4 kb amplified product relative to the entire FIV gp 160 envelope protein is illustrated in Figure 2. The 0.4 kb amplified product was digested with restriction enzyme BamHI which only cuts the linker region of each primer (refer to Figure 1). The BamHI cut PCR product was purified and cloned into BamHI restricted expression vector pLCBCO to generate clone pLCBCOFIV0.4.

Plasmid pLCBCO is an E. coli expression vector that makes use of the bacteriophage lambda pL promoter. pLCBCO is similar to pJL6 described completely in Beltz *et al.*, US Patent No. 4,753,873, incorporated herein by reference.

#### Purification of FIV Recombinant Proteins

E. coli cells were fermented at 32 degrees C to an O.D. 550 of 10.0. The expression of the FIV 0.4 diagnostic protein was induced by temperature shift to 42 degree C for 2 hours. The cells were then harvested by centrifugation at 4000 x g for 20 minutes and lysed by enzymatic digestion with 0.5 mg/ml lysozyme in 50 mM Tris HCl, pH 7.5, containing aprotinin (25

-21-

ug/ml), 2mM PMSF, 25 ug/ml DNase I and 1% Triton-X 100 for 30 minutes with constant stirring. At the end of digestion, the mixture was centrifuged at 12,000 x g for 30 minutes and the resulting pellet was redigested with lysozyme using the same conditions as described above. This was followed by one wash with 0.5% sodium deoxycholate in 50 mM sodium carbonate, pH 10.0. The antigen in the pellet was then solubilized with 0.5% zwittergen 3-14 in the same carbonate buffer. The antigen in the zwittergen supernatant was precipitate by adjusting pH of the solution to 6.0, resolubilized in 6M guanidine HCl, 50 mM borate, pH 9.0, 0.2% beta-mercaptoethanol, alkylated with iodoacetic acid at 1.2 fold molar excess over beta-mercaptoethanol and finally dialyzed against 8M urea, 50 mM borate pH 9.0.

The alkylated dialyzed antigen was then citraconylated by the addition of a 50 fold molar excess of citraconic anhydride (over protein amino groups). After citraconylation, the antigen solution was dialyzed exhaustively against 50 mM sodium borate, pH 9.0 and loaded onto a DEAE-TSK column equilibrated with the same buffer. The DEAE-TSK column was then developed with a linear gradient of 0-1M NaCl to obtain purified recombinant antigen.

Figure 3 shows the purified recombinant proteins. Lane 1 contains molecular weight markers. Lane 2 is the FIV 1.2 envelope gene. Lane 3 is the FIV 0.6 p24 gag protein and lane 4 is the FIV 0.4 envelope protein.

#### Use of the FIV 0.4 Protein in Detection of FIV Infection in Cats

In the use of the FIV 0.4 envelope protein for diagnosis of FIV infection, the purified protein was



-22-

electrophoresed through acrylamide gels and the protein transferred by Western blot to nitrocellulose membranes. Individual strips containing FIV 0.4 protein were reacted with sera from 10 FIV infected cats and with 5 negative controls. The results are shown in Figure 4.

#### EXAMPLE 2

##### Construction of an FIV gag Expressing Clone (FIV 0.6)

The same genomic DNA that was used for PCR in Example 1 was also used in this example. FIV published sequence data (Talbot *et al.*, Proc. Natl. Acad. Sci. 86:5743 (1989)) was used to create oligonucleotide primers for PCR. These primers amplify a region of FIV gag from position 1050 to 1644 and also contain BamHI restriction sites and GC-rich clamps. The sequences of these primers are:

Primer 3: 5' amplimer, position 1050 to 1069  
5'-CCGGGGATCCGGAGTACCACAATATGTAGC-3'

Primer 4: 3' amplimer, reverse complement of positions 1625 to 1644  
5'-GGCCGGATCCCTTCTAGGGTACTTTCTGGC-3'

The oligonucleotide primers were synthesized and PCR amplification was conducted in the same manner as in Example 1. The resulting 0.6 kb fragment was digested with BamHI, which only cuts in the linker region of each primer. The BamHI restricted PCR product was purified and cloned into BamHI restricted expression vector pLCBC1 to generate the clone pLCBC1FIV0.6

Plasmid pLCBC1 differs from pLBCB0 by the addition of a single base pair just prior to the BamHI cloning site. pLCBC1 was used in this case over

-23-

pLCBC0 to allow for proper reading frame alignment. pLCBC1 is also described in Beltz et al., U.S. Patent No. 4,753,873, incorporated herein by reference.

The resulting plasmid was transferred into  
5 E. coli host MZ-1 for expression as in Example 1.

### EXAMPLE 3

#### Construction of an FIV Envelope Expressing Clone (FIV 1.2)

The same genomic DNA that was used for PCR in  
10 Examples 1 and 2 was also used in this example. FIV  
published sequence data (Talbot et al., Proc. Natl.  
Acad. Sci. 86:5743 (1989)) was used to create  
oligonucleotide primers for PCR. These primers  
15 amplify a region of FIV envelope from position 6996 to  
8129, but do not contain BamHI restriction sites for  
GC-rich clamps. The sequences of these primers are:

Primer 5: 5' amplimer, position 6996 to 7025  
5'ACTAGACAATGTAGAAGAGGCAGAATATGG-3'

Primer 6: 3' amplimer, reverse compliment of  
20 positions 8101 to 8129  
5'-TGTTGCAAGAGCCAACATAACATGAATAGC-3'

The oligonucleotide primers were synthesized and  
PCR amplification was conducted in the same manner as  
in Examples 1 and 2. The resulting 1.2 kb fragment  
25 was ligated to BamHI linkers (New England Biolabs  
#1003). The resulting BamHI-linked PCR product was  
digested with BamHI, purified and cloned into BamHI  
restricted expression vector pLCBC2 to generate the  
clone pLCBC2FIV1.2.

30 Plasmid pLCBC2 differs from pLCBC0 by the  
addition of two base pairs just prior to the BamHI  
cloning site. pLCBC2 was used in this case over  
pLCBC0 to allow for proper reading frame alignment.

-24-

PLCBC2 is also described in Beltz et al., U.S. Patent No. 4,753,873, incorporated herein by reference.

The resulting plasmid was transferred into E. coli host MZ-1 for expression as in Examples 1 and 2.

From the foregoing, those of skill will appreciate that, although specific embodiments of the invention have been described herein for illustrative purposes, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

International Application No: PCT/

MICROORGANISMS	
Optional Sheet in connection with the microorganism referred to on page <u>3</u> , line <u>24</u> of the description <sup>1</sup>	
<b>A. IDENTIFICATION OF DEPOSIT <sup>1</sup></b>	
Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depository institution <sup>4</sup> AMERICAN TYPE CULTURE COLLECTION	
Address of depository institution (including postal code and country) <sup>4</sup> 12301 Parklawn Drive Rockville, Maryland 20852 United States of America	
Date of deposit <sup>4</sup> 26 March 1991	Accession Number <sup>4</sup> 68566
<b>B. ADDITIONAL INDICATIONS <sup>1</sup></b> (leave blank if not applicable). This information is continued on a separate attached sheet <input type="checkbox"/>	
<u>Escherichia coli</u> MZ-1, pLCBCOFIVO.4  <i>The following is a preliminary description of the original deposit returned to the depositor for signature and date 12/10/92</i>	
<b>C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE <sup>1</sup></b> (if the indications are not for all designated States)	
<b>D. SEPARATE FURNISHING OF INDICATIONS <sup>1</sup></b> (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later <sup>1</sup> (Specify the general nature of the indications e.g., "Accession Number of Deposit")          	
<b>E.</b> <input type="checkbox"/> This sheet was received with the international application when filed (to be checked by the receiving Office)	
(Authorized Officer)	
<input type="checkbox"/> The date of receipt (from the applicant) by the International Bureau <sup>1</sup>	
(Authorized Officer)	

-26-

We Claim:

1. Recombinant feline immunodeficiency virus (FIV) gp160 envelope protein obtained from cells infected with FIV.
- 5        2. Recombinant FIV 0.4 envelope protein obtained from cells infected with FIV.
3. The FIV envelope protein of claim 1 or 2 produced by E. coli.
4. The FIV envelope protein of claim 1 or 2  
10        produced from E. coli strain MZ-1.
5. A plasmid comprising a DNA sequence coding for a FIV 0.4 envelope protein.
6. A plasmid comprising a DNA sequence coding for a FIV gp160-containing protein.
- 15        7. A plasmid comprising a DNA sequence coding for the FIV envelope protein of Bangstom strain.
8. A eukaryotic cell transformed with the plasmid of claim 5, 6 or 7.
- 20        9. A method of producing FIV 0.4 envelope protein, comprising culturing the transformed cell of claim 8 under conditions allowing expression of FIV 0.4 envelope protein, and recovering said protein.

-27-

10. A method as claimed in claim 9, wherein said DNA sequence is derived from FIV Bangstom strain.

11. An antibody against the FIV envelope protein of claim 1.

5 12. An antibody against the FIV envelope protein of claim 2.

13. An antibody against the FIV envelope protein of claim 3.

10 14. An antibody against the FIV envelope protein of claim 4.

15 15. The antibody of claim 11 or 12, wherein said antibody is selected from the group consisting of a monoclonal antibody, polyclonal antibody, an anti-idiotypic antibody, and an anti anti-idiotypic antibody.

20 16. The antibody of claim 13, wherein said antibody is selected from the group consisting of a monoclonal antibody, polyclonal antibody, an anti-idiotypic antibody, and an anti anti-idiotypic antibody.

25 17. The antibody of claim 14, wherein said antibody is selected from the group consisting of a monoclonal antibody, polyclonal antibody, an anti-idiotypic antibody, and an anti anti-idiotypic antibody.

-28-

18. A method of purifying FIV comprising contacting a sample containing FIV with the antibody of claim 11, 12, 13, 14, 36, or 49 so as to form a complex between FIV in said sample and said antibody, and removing the FIV from said antibody so as to obtain purified FIV.

19. A method of detecting FIV in a sample comprising contacting said sample with the antibody of claim 11, 12, 13, 14, 36, or 49 wherein said antibody is detectably labeled, so as to form a complex between FIV in said sample and said detectably labeled antibody, and detecting the complexed or uncomplexed detectably labeled antibody.

20. A kit for the detection of FIV in a sample, comprising container means comprising one or more containers, wherein one of said containers comprises the antibody of claim 11, 12, 13, 14, 36, or 49, wherein said antibody is detectably labeled.

21. A pharmaceutical composition comprising the antibody of claim 11, 12, 13, 14, 36 or 49.

22. A process for the preparation of a pharmaceutical composition useful for inducing the production in a cat of antibodies to FIV, the process comprising admixing an immunologically effective amount of the polypeptide comprising the amino acid sequence of the FIV gp160 or FIV 0.4 envelope protein together with a pharmacologically acceptable carrier.

-29-

23. A pharmaceutical composition for the prevention of FIV infection comprising the FIV envelope protein of claim 1 or 2.

5 24. A pharmaceutical composition for the prevention of FIV infection comprising the FIV envelope protein of claim 3.

25. A pharmaceutical composition for the prevention of FIV infection comprising the FIV envelope protein of claim 4.

10 26. The use of the pharmaceutical composition of claim 23, in the preparation of a composition for immunizing a cat against FIV.

15 27. The use of the pharmaceutical composition of claim 24, in the preparation of a composition for immunizing a cat against FIV.

28. The use of the pharmaceutical composition of claim 25, in the preparation of a composition for immunizing a cat against FIV.

20 29. Recombinant feline immunodeficiency virus (FIV) 1.2 envelope protein obtained from Bangston strain.

30. The FIV envelope protein of claim 29 produced by E. coli.

25 31. The FIV envelope protein of claim 29 produced from E. coli strain MZ-1.



-30-

32. A plasmid comprising a DNA sequence coding for a FIV 1.2 envelope protein.

33. A eukaryotic cell transformed with the plasmid of claim 32.

5           34. A method of producing FIV 1.2 envelope protein, comprising culturing the transformed cell of claim 33 under conditions allowing expression of FIV 1.2 envelope protein, and recovering said protein.

10           35. A method as claimed in claim 34, wherein said DNA sequence is derived from Bangston strain.

36. An antibody against the FIV envelope protein of claim 29.

15           37. The antibody of claim 36, wherein said antibody is selected from the group consisting of a monoclonal, polyclonal antibody, an anti-idiotypic antibody, and an anti anti-idiotypic antibody.

20           38. A process for the preparation of a pharmaceutical composition useful for inducing the production in a cat of antibodies to FIV, the process comprising admixing an immunologically effective amount of the polypeptide comprising the amino acid sequence of the FIV 1.2 envelope protein together with a pharmacologically acceptable carrier.

25           39. A pharmaceutical composition for the prevention of FIV infection comprising the FIV envelope protein of claim 29.

-31-

40. The use of the pharmaceutical composition of claim 39, in the preparation of a composition for immunizing a cat against FIV.

5 41. Recombinant feline immunodeficiency virus (FIV) gag 0.6 fragment obtained from Bangstom strain.

42. The FIV gag 0.6 fragment of claim 41 produced in E. coli.

43. The FIV gag 0.6 fragment of claim 41 produced from E. coli strain MZ-1.

10 44. A plasmid comprising a DNA sequence coding for a FIV gag 0.6 fragment.

45. A plasmid comprising a DNA sequence coding for the FIV gag 0.6 fragment of Bangstom strain.

15 46. A eukaryotic cell transformed with the plasmid of claim 44 or 45.

47. A method of producing FIV gag 0.6 fragment, comprising culturing the transformed cell of claim 46 under conditions allowing expression of FIV gag 0.6 fragment, and recovering said fragment.

20 48. A method as claimed in claim 47, wherein said DNA sequence is derived from Bangstom strain.

49. An antibody against the FIV gag 0.6 fragment of claim 41.

-32-

50. The antibody of claim 49, wherein said antibody is selected from the group consisting of a monoclonal antibody, polyclonal antibody, an anti-idiotypic antibody, and an anti anti-idiotypic antibody.

51. A process for the preparation of a pharmaceutical composition useful for inducing the production in a cat of antibodies to FIV, the process comprising admixing an immunologically effective amount of the polypeptide comprising the amino acid sequence of the FIV gag 0.6 fragment together with a pharmacologically acceptable carrier.

52. A pharmaceutical composition for the prevention of FIV infection comprising the FIV gag 0.6 fragment of claim 41.

53. The use of the pharmaceutical composition of claim 52, in the preparation of a composition for immunizing a cat against FIV.

54. A kit for detecting FIV antibodies in a sample comprising a carrier being compartmentalized to receive one or more container means in close confinement therein, a first container means comprising a peptide fragment according to any one of claims 1, 2, 29 or 41 immobilized on a solid phase immunoabsorbent and a second container means containing detectably labeled anti-antibody to FIV antibodies.

55. A kit for detecting the FIV virus or proteins thereof in a sample comprising a carrier

-33-

being compartmentalized to receive one or more container means in close confinement therein, a first container means containing an antibody according to any one of claims 11, 12, 36 or 49 immobilized on a solid phase immunoabsorbent and second container means comprising a detectably labeled anti-antibody to said first antibody.

5

56. A plasmid comprising a DNA sequence coding for the FIV envelope protein of claim 5 or 6 of the Bangstom strain.

10

1/4

Primer 1: position 8178 to 8204 (5' ampilmer)  
5'-GGGCCCCGGATCCGGTACACAAATACCACCAGTTCTGGC-3'

Primer 2: Reverse complement of position 8551 to 8578 (3' ampilmer)  
5'-CCCCGGGGATCCCTTCCACTTTGTAAATTGTTGTATCCC-3'

Figure 1: The sequences of the PCR primers. The underlined regions indicate BamHI restriction sites.

2/4




FIGURE 2

3/4





Figure 3. Purified FIV recombinant proteins. Lane 1 are molecular weight markers. Lane 2 is the FIV 1.2 envelope protein. Lane 3 is the p24 gag protein and Lane 4 is the purified recombinant FIV 0.4 diagnostic protein.

FIGURE 3

FIGURE 4





## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US92/01421

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/403, 395, 413, 424/89, 86; 435/5, 7.1, 69.3, 70.21, 252.3, 252.33, 320.1, 975; 436/543, 547, 548; 935/12, 22, 70, 73

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

N-GeneSeq 6; APS; STN/Chemical Abstracts; DIALOG/Biosis, Derwent World Patent Index, Biotechnology Abstracts, Current Biotechnology Abstracts

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO, A, 90/13573 (ANDERSON ET AL) 15 NOVEMBER 1990, <u>especially page 6, lines 1-11,</u> pages 15-20, and page 21, lines 2-9.	5-6, 11-12, 15, 18-19, <u>32, 36-37, 44, 49-50</u> 1-4, 7-10, 13-14, 16-17, 20-31, 33-35, 38-43, 45- 48, 51-56
Y	JOURNAL OF GENERAL VIROLOGY, Volume 71, Part 3, issued March 1990, R. Steinman et al, "Biochemical and immunological characteriza-tion of the major structural proteins of feline immunodeficiency virus", pages 701-706, see entire document.	1-56
Y	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, Vol. 86, No. 15, issued August 1989, R. L. Talbott et al, "Nucleotide sequence and genomic organization of feline immunodeficiency virus", see entire document.	1-56
Y	SCIENCE, Vol. 228, issued 05 April 1985, N. T. Chang et al, "Expression in <u>Escherichia coli</u> of Open Reading Frame Gene Segments of HTLV-III", pages 93-96, see entire document.	1-17, 21, 23-37, 39-50, 52-53, 56

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be part of particular relevance

\*E\* earlier document published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search

29 June 1992

Date of mailing of the international search report

13 JUL 1992

Name and mailing address of the ISA/  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

WILLIAM W. MOORE

Telephone No. (703) 308-0583

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/01421

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ANALYTICAL BIOCHEMISTRY, Vol. 151, No. 2, issued December 1985, D. Pauletti et al, "Application of a Modified Computer Algorithm in Determining Potential Antigenic Determinants Associated with the AIDS Virus Glycoprotein", pages 540-546, see entire document.	1-10, 23-35, 39-40, 56
Y	CELL, Vol. 45, No. 5, issued 06 June 1986, B. R. Starcich et al, "Identification and Characterization of Conserved and Variable Regions in the Envelope Gene of HTLV-III/LAV, the Retrovirus of AIDS", pages 637-648, see entire document, especially figures 2 and 3.	1-10, 23-35, 39-40, 56
Y	JOURNAL OF VIROLOGY, Vol. 61, No. 2, issued February 1987, S. Modrow et al, "Computer-Assisted Analysis of Envelope Protein Sequences of Seven Human Immunodeficiency Virus Isolates: Prediction of Antigenic Epitopes in Conserved and Variable Regions", pages 570-578, see entire document, especially tables 1 and 2 and figure 3.	1-10, 23-35, 39-40, 56
Y	VIROLOGY, Vol. 164, No. 2, issued June 1988, G. Gurgo et al, "Envelope Sequences of Two New United States HIV-1 Isolates", pages 531-536, see entire document, especially figure 2.	1-10, 23-35, 39-40, 56
Y	VIROLOGY, Vol. 181, No. 2, issued June 1988, G. Zwart et al, "Immunodominance and Antigenic Variation of the Principal Neutralization Domain of HIV-1", pages 481-489, see pages 482-487, especially tables 1 and 2 and figures 2 and 3.	11, 15, 19-23, 36-39
Y	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, Vol. 83, No. 14, issued July 1986, R. L. Willey et al, "Identification of conserved and divergent domains within the envelope gene of the acquired immuno-deficiency syndrome retrovirus", pages 5038-5042, see pages 5039-5042, especially figures 1, 3 and 4.	11, 15, 18-23, 29-40, 54
Y	CELL, Vol. 46, No. 1, issued 04 July 1986, M. Alizon et al, "Genetic Variability of the AIDS Virus: Nucleotide Sequence Analysis of Two Isolates from African Patients", pages 63-74, see pages 64-66 and 68-72.	1-11, 29-35, 41-48, 56
Y	US, A, 4,952,784 (CROWL ET AL) 15 MAY 1990, see columns 3-5, 7-9, 11-18.	41-53, 55
Y <sup>4</sup>	US, A, 4,784,941 (WATANABE ET AL) 15 NOVEMBER 1988, see columns 2-13 and figures 3-6.	2-7, 9-10, 12-28
Y	US, A, 4,808,536 (CHANG ET AL) 28 FEBRUARY 1989, see entire document, especially columns 9-13, figure 5 and table 1.	41-55
Y	US, A, 4,753,873 (BELTZ ET AL) 28 JUNE 1988 see columns 4-19 and claims 4-17.	4, 11-17, 19-20, 31, 36-37, 43, 49-51, 54-55
Y	US, A, 4,772,547 (HEIMER ET AL) 20 SEPTEMBER 1988, see columns 4-14, claims 14-20 and figure 1.	12, 15, 19-20, 36-37, 54-55
Y	WO, A, 87/06260 (KIENY ET AL) 22 OCTOBER 1987, see pages 6-8, 15-20, 26, 31-34, and figure 5 and claims 1, 4-6 and 25-37.	1-17, 23-37, 39-40, 54-56
Y	EP, A, 0,279,688 (BERMAN ET AL) 24 AUGUST 1988, see pages 3-10, 13-15, especially pages 5-6, lines 49-11.	29-37, 54-55
Y	EP, A, 0,219,106 (BANNWARTH ET AL) 22 APRIL 1987, see pages 1-5, 11-13 and 32-36, especially page 4, lines 8-18.	2-3, 5, 8-10, 12-28
Y	EP, A, 0,351,348 (O'CONNOR ET AL) 17 JANUARY 1990, see entire document.	19-20, 54-55

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US92/01421

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP, A, 0,231,914 (GALLO ET AL) 12 AUGUST 1987, see pages 6-25, especially pages 8-9, lines 36-13, and claims 1, 11-15, 21-22, 25, 27-28, 30-35, 38.	29-40, 54-55
Y	FEBS LETTERS (Federation of European Biochemical Societies), Vol. 218, No. 2, issued 29 June 1987, M. J. E. Sternberg et al, "Prediction of antigenic determinants and secondary structures of the major AIDS virus proteins", pages 231-237, see entire document.	1-10, 23-35, 39-49, 51-54, 56
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, Vol. 86, No. 14, issued October 1989, P. Rossi et al, "Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to sero-positive mothers", pages 8055-8058.	20-28, 38-40
A,P	JOURNAL OF GENERAL VIROLOGY, Vol. 72, Part 3, issued March 1991, M. Fevereiro et al, "Characterization of two monoclonal anti-bodies against feline immunodeficiency virus gag gene products and their application in an assay to evaluate neutralizing antibody activity", pages 617-622, see pages 619-621 and figure 2.	49-50, 55
A	JOURNAL OF CELLULAR BIOCHEMISTRY, Vol. 4, Supplement 14D, issued February 1990, J. K. Battles et al, "Serological Identification and Baculovirus Expression of Structural Gene Products of the Bovine Immunodeficiency-like Virus (BIV)", page 130, abstract L 302.	1, 5-17, 19, 41, 44-50, 56
A	JOURNAL OF CELLULAR BIOCHEMISTRY, Vol. 4, Supplement 14D, issued February 1990, J. H. Nunberg et al, "Recombinant Thymidine Kinase-Deficient Feline Herpesviruses as Live Vectors for Retrovirus Vaccination in Cats", page 140, abstract L 332.	1-56
T	ARCHIVES OF VIROLOGY, Vol. 122, Nos. 3-4, issued April 1992, T. Furuya et al, "Expression of feline immunodeficiency virus gag gene in <i>Escherichia coli</i> ", pages 383-390.	41-42, 44-45
A	VIROLOGY, Vol. 186, No. 2, issued February 1992, S. Morikawa et al, "Identification of the gag-pol Ribosomal Frameshift Site of Feline Immunodeficiency Virus", pages 389-397.	1-56
A	VIROLOGY, Vol. 179, No. 1, issued November 1990, S.-L. Hu et al, "Processing, Assembly and Immunogenicity of Human Immunodeficiency Virus Core Antigens Expressed by Recombinant Vaccinia Virus", pages 321-329.	41, 44-47
A	JOURNAL OF GENERAL VIROLOGY, Vol. 72, Part 1, issued January 1991, B. R. Brodeur et al, "Monoclonal idiotype and anti-idiotypic antibodies to human immunodeficiency virus type 1 envelope glycoprotein", pages 51-58.	1-56
A	JOURNAL OF VIROLOGY, Vol. 63, No. 1, issued January 1989, M. L. Poss et al, "Posttranslational Modifications Distinguish the Envelope of Immunodeficiency Disease Inducing Feline Leukemia Virus Retrovirus", pages 189-195.	1-56
A	JOURNAL OF VIROLOGY, Vol. 64, No. 6, issued June 1990, O. Haffar et al, "Human Immunodeficiency Virus-Like, Non-Replicating, gag-env Particles Assemble in a Recombinant Vaccinia Virus Expression System, pages 2653-2659.	1-56
A	JOURNAL OF VIROLOGY, Vol. 64, No. 9, issued September 1990, B. Janvier et al, "Linear B-Cell Epitopes of the Major Core Protein of Human Immunodeficiency Virus Types 1 and 2", pages 4258-4263.	1-56

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US92/01421

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF VIROLOGY, Vol. 64, No. 9, issued September 1990, M. L. Poss et al, "Characterization and Significance of Delayed Processing of the Feline Leukemia Virus FeLV-FAIDS Envelope Glycoprotein", pages 4338-4345.	1-56
A	AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol. 6, No. 3, issued March 1990, V. J. P. Teeuwssen et al, "Production and Characterization of a Human Monoclonal Antibody, Reactive with a Conserved Epitope on gp41 of Human Immunodeficiency Virus Type 1", pages 381-392.	1-56
Y	EP, A, 0,255,190, (PUTNEY ET AL) 03 FEBRUARY 1988, see pages 3-4, lines 27-8, from line 28 of page 8 through line 4 of page 17, pages 25-31, and figure 3 and claims 2-3, 5-6, 8-9 and 11-25.	2, 5, 8-10, 21-23, 26, 29, 32-35, 38-40, 54
A	AIDS RESEARCH AND HUMAN RETROVIRUSES, Vol. 7, No. 1, issued January 1991, A. N. Vzorov et al, "Highly Immunogenic Human Immuno-deficiency Viruslike Particles are Produced by Recombinant Vaccinia Virus-Infected Cells", pages 29-36.	1-56
A	JOURNAL OF MEDICAL VIROLOGY, Vol. 30, No. 3, issued March 1991, J. C. Tardy et al, "Blocking-ELISA for Detection of Specific Antibodies to the Glycoproteins of the Human Immunodeficiency Virus Tyoe 1 (HIV-1)", pages 206-210.	1-56

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
PCT/US92/01421

**A. CLASSIFICATION OF SUBJECT MATTER:**  
IPC (5):

C12N 15/49, 15/70, 15/79; C12P 21/08; A61K 39/21, 39/42; G01N  
33/53, 33/564, 33/569

**A. CLASSIFICATION OF SUBJECT MATTER:**  
US CL :

530/403, 395, 413; 424/89, 86; 435/5, 7.1, 69.3, 70.21, 252.3,  
252.33, 320.1, 975; 436/543, 547, 548; 935/12, 22, 70, 73